Acute Lymphoblastic Leukemia: The Current and Future State of Care - Episode 8

Recently Presented Data Informing the Treatment of Patients with Philadelphia Chromosome-negative Acute Lymphoblastic Leukemia

February 27, 2023

Ryan D. Cassaday, MD, University of Washington/Fred Hutch, Elias Jabbour, MD, MD Anderson Cancer Center, Gary J. Schiller, MD, Armin Ghobadi, MD

The panelists review highly anticipated results from the E1910 trial assessing combination blinatumomab/consolidation chemotherapy in patients with Philadelphia chromosome-negative ALL.

EP. 1: Patient Presentation and Diagnosis in Acute Lymphoblastic Leukemia

EP. 2: Differentiating Subtypes of Acute Lymphoblastic Leukemia

EP. 3: Emergent Data Concerning Risk Factors for Acute Lymphoblastic Leukemia

EP. 4: Standard Prognoses for Pediatric and Adult Patients with Acute Lymphoblastic Leukemia

EP. 5: Assessing Minimal Residual Disease in Patients with Acute Lymphoblastic Leukemia

EP. 6: Treatment Options for Patients with Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia in the Frontline Setting

EP. 7: The Evolving Treatment Paradigm for Patients with Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia

Now Viewing

EP. 8: Recently Presented Data Informing the Treatment of Patients with Philadelphia Chromosome-negative Acute Lymphoblastic Leukemia

EP. 9: Considerations for the Treatment of Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia

EP. 10: CAR T-cell Therapy in Patients with R/R Acute Lymphoblastic Leukemia

EP. 11: Inotuzumab as an Option for Patients with R/R Acute Lymphoblastic Leukemia

EP. 12: Applications for Blinatumomab in Treating Patients with R/R Acute Lymphoblastic Leukemia

EP. 13: Emerging Data Supporting the use of Tisagenlecleucel in Patients with R/R Acute Lymphoblastic Leukemia

EP. 14: On the Horizon: Exciting Prospects in the Acute Lymphoblastic Leukemia Treatment Landscape